Ripple Therapeutics Enters Evaluation and Licensing Agreement with Bausch + Lomb

Ripple Therapeutics, a clinical-stage company developing polymer-free sustained release drug delivery systems, has entered into an evaluation and licensing option agreement with an affiliate of Bausch + Lomb.

Advancing Polymer-Free Controlled Drug Delivery

Ripple’s proprietary technology platform is based on the discovery that drugs can be chemically engineered into controlled-release prodrugs without relying on polymers, a component often associated with inflammation. These prodrugs utilize a surface erosion mechanism, enabling zero-order release kinetics, and can be precisely engineered to control both drug dose and duration.

Agreement Terms and Scope

As part of the agreement, Bausch + Lomb will fund early-stage feasibility and preclinical evaluation of a selected target molecule. The company also holds an option to license any of the formulations evaluated under this collaboration. Licensing would be subject to additional financial terms, including milestone payments and royalties.

Leadership Commentary

“We’re pleased to partner with Bausch + Lomb and look forward to working with them to develop sustained release implants that will benefit patients with extended duration and improved safety,” said Tom Reeves, President and CEO of Ripple Therapeutics.

This collaboration aims to advance sustained-release ophthalmic therapies that may offer improved safety profiles and extended treatment duration.